The board would be mad to entertain a deal now. Denial is completely right with his 3 reasons. Any deal now would be based on Phase 2 data and grossly undervalued relative to revenue potential once we have registration past P3 trial.
We don't need a partner leading into P3 trials - we have the tick from the EMA, FDA meeting in the works and TGA to come. The story is becoming more and more de-risked with every announcement. Once the first lot of P3 data is out next year and we've already had the ok from the agencies to register after the trial is complete, our bargaining power will be immense.
YIN AND YANG Part 2, page-11
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.0¢ |
Change
0.005(2.56%) |
Mkt cap ! $70.04M | |||
| Open | High | Low | Value | Volume |
| 20.5¢ | 21.0¢ | 20.0¢ | $52.23K | 254.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 100236 | 20.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.5¢ | 19056 | 3 |
View Market Depth
| Last trade - 10.15am 10/10/2024 (20 minute delay) ? |
| PAR (ASX) Chart |